Efficacy of Botulinum toxin A in treatment of primary hemifacial spasm

2021 ◽  
Vol 25 (2) ◽  
pp. 86-93
Author(s):  
Hue Linh Truong ◽  
Van Lieu Nguyen
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Rating Scale ◽  
Botulinum Toxin A ◽  
Vascular Compression ◽  
Toxin A ◽  
Disability Rating Scale ◽  
Study Results ◽  
Botulinum Toxin Treatment ◽  
Disability Rating

Objective: Evaluating the effects of toxin botulinum A in treatment of primary hemifacial spasm. Methods: A total of 48 patients with primary hemifacial spasm were treated by injections of botulinum toxin A (Dysport) in Tam Anh Hospital from 6/2020 to 5/ 2021. Methods: Prospective, descriptive study. Results: Forty-eight patients (8 male, 40 female) were included in the study, the ages were from 36 to 79 years with an average age of 57 ± 10,43 years, having mean Jankovic disability rating scale score of 3.25±0.55SD. MRI revealed vascular compression in all patients. The dose Dysport was 80-145UI; 91,7% reported improvement after 2 weeks - 1 month from the injected. Benefits begin in 2-7 days after the treatment and last for an average of 5,50 ± 0,97 months (3-8 months). Side effects such as ectropion (45,83%), ptosis (4,2%), and hematoma (12,5%) are transient and reversible after 1-3 weeks. No severe complication was noted. Conclusions: This finding show that local botulinum toxin treatment provides effective and safe relief of hemifacial spasm.

Eight years experience with botulinum toxin A and eyelid surgery in the treatment of hemifacial spasm

2021 ◽  
Vol 2 (2) ◽  
pp. 83-87
Author(s):  
Kenneth K.H. Lai ◽  
◽  
Edwin Chan ◽  
Simon T.C. Ko ◽  
◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Complication Rate ◽  
Botulinum Toxin A ◽  
Onset Time ◽  
Surgical Correction ◽  
Toxin A ◽  
Eyelid Surgery ◽  
Therapeutic Outcomes ◽  
Eyelid Diseases

AIM: To report the therapeutic outcomes of botulinum toxin A (Botox) and eyelid surgery in patients with hemifacial spasm (HFS). METHODS: Patients’ images and medical notes were retrospectively reviewed with subsequent analysis of both the therapeutic outcomes and complications of Botox injections. RESULTS: The information of 76 patients (female=58) with HFS who received a minimum of 4 Botox injections were included. The mean follow-up interval was 83±50 (20-112)mo with an average of 16±10 (4-34) injections. The peak incidence was between 55 and 64 years and the average age of onset was 66±11 (32-85)y. Up to 23% of patients with HFS had aberrant vascular structures (right=8, left=7) in close relationship to the facial nerve (MRI=14, CT=1), where the vertebral artery (n=6) was the most involved vessel followed by the anterior inferior cerebellum artery (n=5). Patients with primary HFS had a shorter effective duration (2.5 vs 3.1mo, P<0.05), a longer onset time (4.1 vs 3.8d, P=0.739) and a lower Subjective Spasm Alleviation score (SSAs; 1.7 vs 1.9, P=0.179) than those with secondary HFS. Twelve of the 19 patients with preexisting eyelid diseases underwent surgical correction including upper blepharoplasty (n=12), limited myectomy (n=7), browplasty (n=7) and advancement of levator aponeurosis (n=5). Five (41.7%) of those with surgical correction and suboptimal response to Botox showed improvement 6mo after surgery [onset time (P=0.0256), effective duration (P=0.374) and SSAs (P=0.0161)]. Those 12 patients with eyelid surgery had a lower complication rate than those without eyelid surgery (23% vs 42%, P≤0.05). CONCLUSION: Botox is an effective and safe treatment for HFS. Patients with primary HFS had a less favorable therapeutic outcome with Botox than those with secondary HFS. Eyelid surgery for patients with concurrent eyelid diseases can augment the effect of subsequent Botox injections by improving patient satisfaction and reducing complication rate.

Low-Dose Botulinum Toxin A for Treatment of Blepharospasm and Hemifacial Spasm

2005 ◽  
Vol 49 (4) ◽  
pp. 327-328 ◽  
Author(s):  
Anuchit Poonyathalang ◽  
Pisit Preechawat ◽  
Uraiwan Jamnansiri
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Low Dose ◽  
Botulinum Toxin A ◽  
Toxin A

Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment

2016 ◽  
Vol 37 (11) ◽  
pp. 1807-1813 ◽  
Author(s):  
Libin Xiao ◽  
Yougui Pan ◽  
Xiaolong Zhang ◽  
Yong Hu ◽  
Li Cai ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin A ◽  
Facial Asymmetry ◽  
Toxin A ◽  
Before And After

Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A

Cornea ◽  
2016 ◽  
Vol 35 (2) ◽  
pp. 220-225 ◽  
Author(s):  
Teissy Osaki ◽  
Midori H. Osaki ◽  
Tammy H. Osaki ◽  
Flavio E. Hirai ◽  
Mauro Campos
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin A ◽  
Toxin A

scholarly journals DEVELOPMENT OF MOTOR FUNCTIONS AND MANUAL ABILITIES IN PEDIATRIC PATIENTS WITH SPASTIC CEREBRAL PALSY AFTER BOTULINUM TOXIN TREATMENT AND COMPLEX REHABILITATION

2013 ◽  
Vol 68 (11) ◽  
pp. 38-48
Author(s):  
O. A. Klochkova ◽  
A. L. Kurenkov ◽  
L. S. Namazova-Baranova ◽  
A. M. Mamed'yarov ◽  
K. V. Zherdev
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Motor Development ◽  
Botulinum Toxin A ◽  
Hand Function ◽  
Spastic Cerebral Palsy ◽  
Toxin A ◽  
Botulinum Toxin Therapy ◽  
Botulinum Toxin Treatment ◽  
Development Assessment

Aim: to investigate the dynamic of general motor function and manual abilities in children with spastic forms of cerebral palsy (CP) after complex rehabilitation combined with single and repeated injections of botulinum toxin A (BTA). Patients and methods: the article presents 18 month follow-up of 52 patients with mono- and bilateral spastic forms of CP after single and multiple injections of botulinum toxin A and complex rehabilitation/ Patients received totally 74 injection sessions: 17 (32,7%) children — twice, 5 (9,6%) children — three times. Motor development assessment was done according to the GMFCS and GMFMS-88 scales and centile curves of normal motor development connected with these scales, hand function was classified according to the MACS scale. For the first time results of botulinum toxin therapy and rehabilitation were compared with the natural motor development of patients with different levels of motor disturbances according to centile tables. Results: patients with bilateral cerebral palsy improved slowly than hemiparetic and changes lasted for longer period. Level according to the MACS scale didn’t depend on the gestational age of the patients, was higher in children with hemiparesis and changed for 1 level in 4 (7,7%) patients after the first botulinum toxin A injections. 

Botulinum toxin A injection in the treatment of hemifacial spasm

1996 ◽  
Vol 94 (3) ◽  
pp. 207-211 ◽  
Author(s):  
R.-S. Chen ◽  
C.-S. Lu ◽  
C.-H. Tsai
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin A ◽  
Toxin A

scholarly journals Botulinum Toxin A Treatment for Primary Hemifacial Spasm

2002 ◽  
Vol 59 (3) ◽  
pp. 418 ◽  
Author(s):  
Giovanni Defazio ◽  
Giovanni Abbruzzese ◽  
Paolo Girlanda ◽  
Laura Vacca ◽  
Antonio Currà ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin A ◽  
Toxin A

scholarly journals A First Clinical Trial on Botulinum Toxin-A for Chronic Muscle-Related Pain in Cerebral Palsy

2021 ◽  
Vol 12 ◽  
Author(s):  
Dan Jacobson ◽  
Kristina Löwing ◽  
Kjell Kullander ◽  
Britt-Marie Rydh ◽  
Kristina Tedroff
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Interim Analysis ◽  
Primary Outcome ◽  
Rating Scale ◽  
Botulinum Toxin A ◽  
Spastic Cerebral Palsy ◽  
Number Needed To Treat ◽  
Toxin A ◽  
Reduction Of Pain

Objective: To test if botulinum toxin-A (BoNT-A) is effective in reducing chronic muscle-related pain in adults with spastic cerebral palsy (CP), as compared to placebo.Design: A single-center, double-blind, parallel, randomized placebo-controlled trial. The design included an interim analysis to allow for confirmatory analysis, as well as pilot study outcomes.Setting: Tertiary university hospital.Participants: Adults with spastic CP and chronic pain associated with spastic muscle(s).Intervention: Treatment was one session of electromyographically guided intramuscular injections of either BoNT-A or placebo normosaline.Main Study Outcomes: The primary outcome was the proportion who achieved a reduction of pain intensity of two or more steps on the Numerical Rating Scale 6 weeks after treatment.Results: Fifty individuals were screened for eligibility, of whom 16 were included (10 female, 6 male, mean age = 32 years, SD = 13.3 years). The randomization yielded eight participants per treatment arm, and all completed the study as randomized. The study was stopped at the interim analysis due to a low probability, under a preset threshold, of a positive primary outcome. Four individuals were treatment responders in the BoNT-A group for the primary outcome compared to five responders in the placebo group (p = 1.000). Adverse events were mild to moderate. In exploratory analysis, the BoNT-A group had a trend of continuing reduction of pain at the last follow-up, after the primary endpoint.Conclusions: This study did not find evidence that BoNT-A was superior to placebo at the desired effect size (number needed to treat of 2.5) at 6 weeks after treatment.Trial registration:ClinicalTrials.gov: NCT02434549

Sign in / Sign up

Export Citation Format

Share Document